Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG017 in advanced breast cancer
NCT05673694Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Nov 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of EG-017 in breast cancer (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Safety and Tolerability (DLTs, AEs, SAEs) at 28 days and Clinical Benefit Rate at 24 weeks. Started Mar 2023; status: recruiting.
02
Drugs
EG-017
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05673694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673694.